Losing 2 stone in 10 weeks on Wegovy: what the data says

What did @leelaknight actually say?

In short: she lost 2 stone 2.5 pounds in 10 weeks on Wegovy, noticed her appetite suppression felt like it was "lessening" despite dose increases, and is considering switching injection sites based on anecdotal reports that the back of the arm produces better results than the abdomen.

She doesn't make wild clinical claims. She's sharing a personal experience and a theory she picked up from other users online. She's careful to hedge: "apparently like changing up your injection site does like really help" and "that could be different for you." That kind of caveat is more responsible than a lot of what circulates in this space. The weight loss figure she cites is specific and self-reported, not dramatised. The injection site discussion is where things get more complicated.

Does the science back this up?

The weight loss rate is plausible but sits near the top of what trials show. The injection site claim has some pharmacokinetic logic behind it, but the evidence is thinner than TikTok would have you believe.

On weight loss: the STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed participants lost an average of 14.9% body weight over 68 weeks on 2.4mg semaglutide. Ten weeks in, losses vary widely. Losing roughly 2 stone from a starting weight we don't know is within the plausible range for early responders, particularly at higher doses. Early weight loss on GLP-1 agonists tends to be faster before plateauing.

On injection sites: subcutaneous bioavailability of semaglutide is approximately 89% regardless of site, according to Novo Nordisk's own pharmacokinetic data. The approved sites, abdomen, thigh, and upper arm, are considered clinically equivalent for absorption. There is no published peer-reviewed evidence that the upper arm produces meaningfully greater appetite suppression than the abdomen in humans.

What did they get wrong (or right)?

The injection site theory is the weakest part of this video. She's right that the upper arm, thigh, and abdomen are all approved injection sites. She's wrong, or at least unsubstantiated, in implying that site choice meaningfully changes appetite suppression outcomes.

The anecdote she references, people "still starving" from abdominal injections but fine after switching to the arm, is exactly the kind of n=1 signal that social media amplifies into received wisdom. There are plausible reasons why individuals might notice differences: injection technique, needle depth, tissue composition, and the natural ebb and flow of GLP-1 effects over a dosing week can all create the impression of a site-specific effect. But the impression isn't the mechanism.

What she got right: rotating injection sites to avoid lipohypertrophy is genuinely good practice. The American Diabetes Association and most GLP-1 prescribing guidelines recommend site rotation precisely because repeated injection into the same spot can impair absorption over time. So if she's been injecting the same abdominal spot for 10 weeks, switching sites is sensible, just not for the reason she thinks.

What should you actually know?

Three things matter here for anyone using or considering Wegovy. First, early weight loss being rapid doesn't mean it will continue at that pace. The STEP 1 trial shows the curve flattens. Managing expectations matters.

Second, if appetite suppression seems to be fading, the more likely explanations are the body adapting to the current dose, the timing of injections relative to eating, or inconsistent injection technique. These are worth discussing with a prescriber rather than troubleshooting through TikTok comments.

Third, the three approved injection sites for semaglutide (abdomen, upper thigh, upper arm) are interchangeable by design. Rotating between them is good practice. Expecting one site to dramatically outperform another is not supported by the pharmacology. A systematic review by Gentilcore et al. (2011, Diabetes Care) on subcutaneous absorption variability found that factors like blood flow, local fat distribution, and injection depth matter more than anatomical region in most cases.

• Rotate injection sites to avoid tissue buildup, not to chase a stronger effect.
• Perceived fading of effects is common and worth flagging to your prescriber.
• Individual variation in GLP-1 response is real, but injection site is unlikely to explain it.

Should you take this video's advice?

Selectively. The personal progress update is fine for what it is: one person's documented experience. The injection site switching advice is based on social proof rather than clinical evidence, which doesn't make it harmful but does make it unreliable. If you're on a GLP-1 medication and feel it's losing effectiveness, talk to whoever prescribed it. Dose timing, storage conditions, injection technique, and dose progression are all variables a clinician can actually assess.